| Biomarker ID | 402 |
| PMID | 19050681 |
| Year | 2009 |
| Biomarker | BCL-2 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Interleukin-7 signaling pathway,BAD phosphorylation regulation,Apoptosis intrinsic pathway,RXR/VDR pathway,Corticotropin releasing hormone pathway |
| Experiment | Localized prostate cancer Vs benign prostate |
| Type of Biomarker | Diagnostic |
| Cohort | 84 patients who had undergone radical prostatectomy, matched for pathological stage, Gleason sum score, preoperative PSA, and paired for relapse and non-relapse status. 41 patients with Relapse, and 41 without relapse. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.01 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | BCL2 |